

Manuscript writing: Nancy T. Sklarin, Svetlana Granovsky, Eileen M. O'Reilly, Andrew Zelenetz

Final approval of manuscript: Nancy T. Sklarin, Svetlana Granovsky, Eileen M. O'Reilly, Andrew Zelenetz

Corresponding author: Nancy T. Sklarin, MD, MS, Memorial Sloan-

Kettering Cancer Center, 1275 York Avenue, New York, NY 10065; e-mail: sklarinn@mskcc.org.

DOI: 10.1200/JOP.2011.000266

References

1. One Hundred Eleventh Congress of the United States of America, The American Recovery and Reinvestment Act of 2009, Title XIII, Health Information Technology, 2009, p 138
2. Blumenthal D, Tavenner M: The "meaningful use" regulation for electronic health records. *N Engl J Med* 363:501-504, 2010
3. Cheriff AD, Kapur AG, Qiu M, et al: Physician productivity and the ambulatory EHR in a large academic multi-specialty physician group. *Int J Med Inform* 79: 492-500, 2010
4. Boonstra A, Broekhuis M: Barriers to the acceptance of electronic medical records by physicians from systemic review to taxonomy and interventions. *BMC Health Services Res* 10:231, 2010
5. Amusan AA, Tongen S, Speedie SM, et al: A time-motion study to evaluate the impact of EMR and CPOE implementation on physician efficiency. *J Healthc Inf Manag* 22:31-37, 2008
6. Collins CM, Elsaid KA: Using an enhanced oral chemotherapy computerized provider order entry system to reduce prescribing errors and improve safety. *Int J Qual Health Care* 23:36-43, 2011
7. Sklarin NT, Granovsky S, Hagerly-Paglia J: Implementation of an electronic health record at an academic cancer center: Lessons learned and strategies for success. *Am Soc Clin Oncol Ed Book* 411-415, 2011
8. Owens K: EMR Implementation: Big bang or a phased approach. *J Med Pract Manage* 23:279-281, 2008
9. Brokel JM, Harrison MI: Redesigning care processes using an electronic health record: A system's experience. *Jt Comm J Qual Patient Saf* 35:82-92, 2009
10. Baker DK, Hoffman JM, Hale GA, et al: Analysis of patient safety: Converting complex pediatric chemotherapy ordering processes from paper to electronic systems, in Henriksen K, Battles JB, Keyes MA, et al (eds): *Advances in Patient Safety: New Directions and Alternative Approaches—Vol 2: Culture and Redesign*. Rockville, MD, Agency for Healthcare Research and Quality, 2008, pp 1-13
11. Campbell EM, Sittig DF, Ash JS, et al: Types of unintended consequences related to computerized provider order entry. *J Am Med Inform Assoc* 13:547-556, 2006



Computerized Provider Order Entry in Pediatric Oncology: Design, Implementation, and Outcomes

By Allen R. Chen, MD, MHS, PhD, and Christoph U. Lehmann, MD, FAAP, FACMI

Departments of Oncology and Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD

Abstract

Purpose: Pediatric oncology is a challenging environment for computerized provider order entry (CPOE). Our goal was to build on the proven safety features of CPOE and facilitate input of expert clinicians.

Methods: A standard, commercially available CPOE system was implemented throughout the hospital. The design of the pediatric oncology implementation was a collaborative effort by a multidisciplinary team of clinicians and information technology experts.

Results: During 9 months of configuration effort, 30 medical logic modules and 110 order sets were developed to support

pediatric oncology. The proportion of chemotherapy orders submitted using specific research protocol or standard-of-care order sets increased from 57% to 84% as the number of active order sets grew to 200. The number of medication-related patient safety events decreased 39% after implementation of CPOE in pediatric oncology. Acceptance of the system is high in all clinical disciplines.

Conclusion: Implementation of CPOE required extensive customization but improved patient safety in this highly complex pediatric oncology environment.

Introduction

Pediatric oncology orders are among the most challenging to implement in a provider order entry system, complicated by medications with narrow therapeutic index and the need to individualize treatment regimens not only by age, weight and size, but also on the basis of prior response to treatment. Clinical criteria must be met before initiation of chemotherapy, and chemotherapy, protective, and rescue medications must be sequenced correctly, thus requiring a reschedule logic that links orders and their start time to prevent injury. Within oncology, pediatric practice is extraordinary in the proportion of patients

treated with curative intent on highly complex, cooperative group clinical trials,^{1,2} each with low accrual per center, and acceptance of grade 4 hematologic and mucosal toxicity. Moreover, long-term adverse effects of therapy are common and serious.^{3,4} Therefore, the consequences of dosing and administration errors are potentially severe, requiring forcing of rescue medications, adequate hydration, and strict dose range checks.

Pediatric Chemotherapy Process at Johns Hopkins Before CPOE

The two cornerstones of chemotherapy safety in pediatric oncology are clarity and independent checks: clarity, so the prescriber's

intent is carried out; and independent checks, so the process can recover from any single human error. In 1995, the Johns Hopkins Division of Pediatric Oncology adopted standard practices for specifying chemotherapy treatment plans and for writing chemotherapy orders that largely anticipated the 2009 ASCO/Oncology Nursing Society standards.⁵ Word processing fill-in-the-blank templates were generated for common regimens. However, between 1998 and 2004, we found that 10 of 26 drug-related sentinel events at The Johns Hopkins Hospital were associated with chemotherapy, of which five involved pediatric oncology patients, reflecting an extraordinary degree of risk. This motivated a failure modes and effects analysis of chemotherapy prescribing, dispensing and administration; the creation of refined policies and procedures; and the in-house development of a first-generation computerized order generation system used to create all printed chemotherapy orders in pediatric oncology.⁶ This system resulted in complete standardization of the format of orders and elimination of calculation errors, but it was limited by the absence of order set functionality, lack of an interface with the pharmacy system, and inability to improve and maintain the system.

We therefore decided to adapt the commercially available provider order entry system selected for use throughout the Johns Hopkins inpatient units for chemotherapy prescribing. The Eclipsys/Allscripts Sunrise system has a versatile security model, and functionality can be added by using Medical Logic Modules (MLMs).

Methods

Design

The design of the pediatric oncology ordering tool was based on the needs assessment of providers and nurses in the pediatric oncology section. They comprised the largest contingent of the implementation team and determined design decisions.

The design was based on the previous chemotherapy ordering system developed at Johns Hopkins, which lacked the ability to design order sets and to communicate with the pharmacy system. The design principles were to include all existing features found to enhance safety, such as height and weight check, automatic hydration, and automatic dose modification, while adding order set functionality to reduce omissions and improve safety and ease of use. A total of 30 MLMs were written to support pediatric oncology ordering (Appendix Table A1, online only).

Weight/height check. Every chemotherapy order set requires that the provider enter height and weight anew with orders to avoid dosing errors. The system automatically calculates body surface area (BSA), body mass index, and ideal body weight and uses an MLM to alert the provider of weights outside the normal ranges published by the Centers for Disease Control and Prevention,⁷ (Appendix Figure A1A, online only) thus reducing measurement and data entry errors.

Hydration orders. Adequate hydration is critical to prevent toxic adverse effects of certain chemotherapy drugs. We designed all order sets with medications that require such hydration to force the provider to include hydration orders (Appendix Figure A1B). An order set with suggested fluid volume allows the pro-

vider to automatically calculate hydration rates by weight or BSA, minimizing the risk for omissions or inaccuracies. All weight- or BSA-based calculations for fluids and medications remain attached to the order to allow downstream providers to understand how doses were derived.

Dose adjustment. Dose adjustments are frequently required because of toxicity or changing metabolism during the course of treatment. Standard practice requires an increase or decrease in dose by a certain percentage from the standard dose. CPOE systems are generally not designed to accommodate this very important safety feature, but by using an order form-based MLM, we were able to implement a percentage dose adjustment that makes the logic explicit to downstream providers. Appendix Figure A1C shows the default dose calculation, and Appendix Figure A1D shows a 25% reduction in dose by the provider.

Order sets. When orders cross the interface from CPOE to the pharmacy system, they appear in a queue with insufficient context for pharmacists to verify chemotherapy orders. To provide that context, we require that all oncology chemotherapy be written on an order set that includes a synopsis order. The synopsis order identifies the treatment regimen or protocol, point in therapy, basis for dose calculation, cumulative anthracycline dose, medication sequence, criteria to begin treatment, and other information pertinent to administration. A synopsis report supports the pharmacy workflow for verification.

At Johns Hopkins, chemotherapy is categorized as research protocols, standard of care, or individualized regimens. Research protocol and standard-of-care order sets cannot be interchanged, because the research protocol order sets may use study-specific medications and special research laboratories. A General Chemotherapy Order Template (GCOT) allows ordering of individualized chemotherapy, including nonformulary and investigational agents, and is also used for standard-of-care and research protocol chemotherapy for which specific order sets have not been constructed. Because of the scrutiny that specific research protocol and standard-of-care order sets receive, a single attending physician signature is sufficient for these orders, but we require that a second pediatric oncology physician review and sign GCOT orders.

Placing orders for one complete cycle of chemotherapy at a time is considered best practice. This approach balances the need for ongoing reassessment of the patient's body size, metabolic function, disease response, and drug toxicity with the need to understand the regimen as a whole, and minimizes the number of times orders are written. In our medium-sized practice, we see 172 newly diagnosed patients per year, and last year enrolled 58 patients on 79 active treatment protocols (Appendix Table A2, online only). To cover every cycle of every protocol or regimen with a specific order set would require several hundred order sets. Because of the low expected accrual per protocol in pediatric oncology, we have adopted a "just-in-time" approach for rarely used protocols. This approach requires an institutional commitment to provide rapid turnaround order sets; our standard is to build, review, test, approve, and make order sets available in the production system within 2 weeks of identifying an urgent patient need for




Figure 1. Process map for the prioritization and development of order sets. The research protocol team includes the principal investigator and research nurse. The information technology team includes an order set analyst, pharmacy information technology (IT), and ancillary IT. The clinical team includes a disease-specific physician leader, clinical nurse specialist, and pharmacy clinical specialist. The order set review committee is chaired by a physician member of the medical board and includes representatives from laboratory medicine, pharmacy, and nursing administration.

a new regimen or a critical amendment. The process for prioritizing the development of order sets is shown in Figure 1.

Implementation

Roll-out. Because of the need for significant MLM programming and testing to support safe chemotherapy prescribing and administration, pediatric oncology was the last unit in the Children's Center to adopt CPOE. Therefore, the pediatric residents and intensive care unit staff were experienced users when CPOE was implemented in pediatric oncology, but chemotherapy prescribers were not.

Our analysis was that the CPOE system, with its electronic Medication Administration Record (eMAR), affects nursing workflow more than physician workflow, and there were major safety concerns with having more than one system in use on a unit. Therefore, adoption of the system was initiated in the nursing unit, not in the physician service.

A timeline of our development and implementation is shown in Appendix Figure A2 (online only). The largest commitment of time and effort was for configuration, primarily developing order sets, and involved five clinical (three nurses, one prescriber, and one pharmacist) and 10 information systems full-time-equivalent staff for 9 months. Implementation began with 110 chemotherapy order sets; 57% of chemotherapy orders were submitted on specific order sets, and the remainder on the

GCOT. Currently, with 200 chemotherapy order sets, 84% of chemotherapy orders are submitted on specific order sets.

Training. The effort of developing order sets and testing resulted in a cadre of "super-users" in each discipline. The ability of these super-users to design training scenarios and coach their peers in the use of the system was a key factor in the success of the implementation, along with the responsiveness of the information systems team, which held daily troubleshooting meetings upon activation of the system.

Prescriber training was done as a two-part process. The first hour consisted of the standard training required by the hospital for all prescribers. This was followed by 2 hours of oncology-specific training, led by a pediatric oncology attending physician involved in system design and configuration. An hour was allotted for each prescriber to work through scenarios in the training system specific to his or her role as an attending, fellow, or physician extender. For example, extenders had to enter orders for planned chemotherapy admissions, fellows had to enter orders for newly diagnosed patients and patients readmitted with complications, and attending physicians had to find and correct errors in orders submitted for their signature. Prescribers who can work from home were asked to test their remote access before implementation.

Nurses received 4 hours of standard training. Eight hours of oncology-specific training, led by pediatric oncology nurse super-users, included 4 hours of competency testing. Two crucial new

processes for nurses were releasing order sets from a chemotherapy hold status and setting the schedule for all chemotherapy on the eMAR.

Pharmacists had used the system when covering other units and received 3 hours of oncology-specific training oriented around test scenarios. Nurses and pharmacists needed to be able to complete the chemotherapy checklist within the new system, including identifying all required elements within the order sets, particularly in the synopsis orders.

Maintenance. A Web-based issues and bug tracking system (JIRA; Atlassian, San Francisco, CA) is used to track areas of concern as well as new requests for medications or order sets. By logging these issues, the provider initiates a cascade of events including analysis of the need, development of a solution, and prioritization, followed by development, testing, and implementation.

The pediatric oncology implementation team continues to meet frequently and prioritize pending requests; the top five are slated for development and testing efforts. By keeping the list small and keeping clinicians and developers abreast of the current status by weekly conference call, delays in critical changes remain at a minimum.

Order sets. The JIRA system is also used to add order sets and maintain changes. Changes in protocols or participation in new study protocols trigger the development of new order sets (Figure 1). By developing “mini-order sets” that are used as modular building blocks for existing order sets (object-based design principle), development time for additional order sets is minimized.

Results

Acceptance

Acceptance of the system was excellent among all three clinical disciplines primarily affected. Importantly, the implementation of the system resulted in benefits for each discipline. Prescribers found that specific order sets reduced the time and effort needed to enter orders. Pharmacy found that workflow changed dramatically but orders were clearer and more complete, so fewer interventions were required. Nursing enjoyed the clarity of orders and consistency of their workflow and noted fewer prescribing errors and quicker pharmacy response.

Safety

When major changes are introduced in clinical systems and workflows, it is important to monitor for a possible increase in errors or the appearance of a new spectrum of errors. We collect and review all medication-related events that occur on our unit and service, and we observed an immediate and profound decrease in events after adoption of CPOE. In the last year before implementation, a total of 132 medication-related events were reported for patients admitted to the pediatric oncology/bone marrow transplantation service on our unit. In the first year after implementation, 80 medication-related events were reported, a decrease of 39%. Of these events, the number that reached the patient similarly decreased by 40%, from 84 to 50. Chemotherapy-related events declined 48%,

from 33 to 17. At baseline, 23% of events involved prescribing, 19% transcription, 39% dispensing, and 50% administration (the total exceeds 100% because multiple processes could be involved in one event). Every process improved after implementation of the CPOE system: prescribing events decreased 67%, transcription events were eliminated, dispensing events decreased 42%, and administration events decreased 33%.

Discussion

This system has not yet been implemented in the outpatient setting. This is an area of current development in which we hope to achieve similar gains. Our orders system is not yet integrated with documentation of the treatment plan, so we still require the prescriber to select the correct order set and identify the point in therapy by using information from the eMAR and hard-copy treatment plans.

Implementation of a CPOE system improved patient safety in a highly complex inpatient pediatric oncology setting. However, considerable effort was required to analyze workflows and add functionality to the system to support the requirements of pediatric oncology. Several months were spent developing order sets and customizing the implementation, a process that depended on and fostered the development of super-users in each discipline who could champion the system and coach their peers in its use. The development of a common syntax for specifying treatment plans and order sets across systems and institutions would significantly advance the safety and efficiency of care.

Accepted for publication on May 22, 2011.

Acknowledgment

Presented in part at the Second Annual Johns Hopkins Medicine Patient Safety Summit, June 21, 2011, Baltimore, MD.

We thank the many clinicians and information technology professionals who contributed to the design and implementation of the CPOE system in pediatric oncology. Alix Dabb, PharmD, was involved in system design and implementation, and provided information on order set utilization. Colleen Reid, RN, and Denise Daniel, RN, MSN, provided pediatric oncology nursing expertise in design, implementation, and training. Pat Zeller manages the system and provided the timeline information. Desiree Baldwin developed most of the MLMs.

Authors' Disclosures of Potential Conflicts of Interest

Although all authors completed the disclosure declaration, the following authors indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a “U” are those for which no compensation was received; those relationships marked with a “C” were compensated. For a detailed description of the disclosure categories, or for more information about ASCO's conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.

Employment or Leadership Position: Christoph U. Lehmann, American Medical Informatics Association (U), Child Health Informatics Center, American Academy of Pediatrics (C), Applied Clinical Informatics (U), eNeonatal Review (C) **Consultant or Advisory Role:** Christoph U. Lehmann, Pediatric Informatics textbook (C) **Stock Ownership:** None **Honoraria:** None **Research Funding:** None **Expert Testimony:** None **Other Remuneration:** None

Author Contributions**Conception and design:** Allen R. Chen, Christoph U. Lehmann**Provision of study materials or patients:** Allen R. Chen**Collection and assembly of data:** Allen R. Chen**Data analysis and interpretation:** Allen R. Chen**Manuscript writing:** Allen R. Chen, Christoph U. Lehmann**Final approval of manuscript:** Allen R. Chen, Christoph U. Lehmann*Corresponding author:* Allen R. Chen, 1650 Orleans St, CRB 2M53, Baltimore, MD 21231; e-mail: chenai@jhmi.edu.

DOI: 10.1200/JOP.2011.000344

References

1. Smith MA, Seibel NL, Altekruse SF, et al: Outcomes for children and adolescents with cancer: Challenges for the twenty-first century. *J Clin Oncol* 28:2625-2634, 2010
2. Baquet CR, Ellison GL, Mishra SI: Analysis of Maryland cancer patient participation in National Cancer Institute-supported cancer treatment clinical trials. *J Clin Oncol* 26:3380-3386, 2008
3. Wasilewski-Masker K, Mertens AC, Patterson B, et al: Severity of health conditions identified in a pediatric cancer survivor program. *Pediatr Blood Cancer* 54:976-982, 2010
4. Yeh JM, Nekhlyudov L, Goldie SJ, et al: A model-based estimate of cumulative excess mortality in survivors of childhood cancer. *Ann Intern Med* 152:409-17: W131-W138, 2010
5. Jacobson JO, Polovich M, McNiff KK, et al: American Society Of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards. *J Clin Oncol* 27:5469-5475, 2009
6. Kim GR, Chen AR, Arceci RJ, et al: Error reduction in pediatric chemotherapy: Computerized order entry and failure modes and effects analysis. *Arch Pediatr Adolesc Med* 160:495-498, 2006
7. Centers for Disease Control and Prevention: Percentile Data Files with LMS Values, August 4, 2009 update. http://www.cdc.gov/growthcharts/percentile_data_files.htm



Implementation of Electronic Checklists in an Oncology Medical Record: Initial Clinical Experience

By Kevin V. Albuquerque, MD, Alexis A. Miller, MD, and John C. Roeske, PhD

Department of Radiation Oncology, Loyola University of Chicago Medical Center, Maywood, IL; Department of Radiation Oncology, Illawarra Cancer Care Centre, Wollongong, New South Wales, Australia

Abstract

Purpose: The quality of any medical treatment depends on the accurate processing of multiple complex components of information, with proper delivery to the patient. This is true for radiation oncology, in which treatment delivery is as complex as a surgical procedure but more dependent on hardware and software technology. Uncorrected errors, even if small or infrequent, can result in catastrophic consequences for the patient. We developed electronic checklists (ECLs) within the oncology electronic medical record (EMR) and evaluated their use and report on our initial clinical experience.

Methods: Using the Mosaik EMR, we developed checklists within the clinical assessment section. These checklists are based on the process flow of information from one group to another within the clinic and enable the processing, confirmation,

and documentation of relevant patient information before the delivery of radiation therapy. The clinical use of the ECL was documented by means of a customized report.

Results: Use of ECL has reduced the number of times that physicians were called to the treatment unit. In particular, the ECL has ensured that therapists have a better understanding of the treatment plan before the initiation of treatment. An evaluation of ECL compliance showed that, with additional staff training, > 94% of the records were completed.

Conclusion: The ECL can be used to ensure standardization of procedures and documentation that the pretreatment checks have been performed before patient treatment. We believe that the implementation of ECLs will improve patient safety and reduce the likelihood of treatment errors.

Introduction

Although accidental overdose is uncommon in radiation oncology, the results are serious for the patient. Recently, the popular press reported on accidents that resulted from failures of equipment, software, and work practices.¹ Although these reports have labeled radiation treatments as unsafe, the objective data suggest that errors (or accidents) are fortunately rare. In New York, where one of the reports originated, the error rate based on an estimate of 13.6 million radiation treatments over the period was 0.005%.² This low rate has been documented by others as well,³ but reported ranges vary from as

high as 0.2% without computerized systems to as low as 0.017% with these systems.³ Even though this error rate is small, and most errors are of no consequence, a single error is one too many.

Technology is a double-edged sword. It can function as a valuable adjunct to the human brain, serving to note and ensure completeness.⁴ However, it can also magnify the scale of errors when it is relied on excessively and taken for granted. Although there have been cases of poorly constructed technology, the majority of errors in radiation oncology result from poor training and individuals not following standard procedures.⁵⁻⁷